Collin Gage, Author at PsyNews.com

Home Authors Posts by Watertime

165 POSTS 0 COMMENTS

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

1...15 1617Page 17 of 17

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime